Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,961 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,853 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02584556 | Adjuvant Transcatheter Arterial Chemoembolization Versus Adjuvant Systemic Chemotherapy for Hepatocellular Carcinoma | withdrawn | Phase 2 / Phase 3 | 0 | Guangxi Medical UniversityOTHER | 0 | Jun 4, 2019 | clinicaltrials |
| NCT02585479 | Systemic Chemotherapy Versus Transcatheter Arterial Chemoembolization(TACE) for Hepatocellular Carcinoma | withdrawn | Phase 2 / Phase 3 | 0 | Guangxi Medical UniversityOTHER | 0 | Jun 4, 2019 | clinicaltrials |
| NCT03773510 | Study on Leiomyosarcoma, Liposarcomas and Synovial Sarcoma With Trabectedin(TRADITIONS) | withdrawn | Phase 3 | 0 | Italian Sarcoma GroupNETWORK | 1 | May 13, 2019 | clinicaltrials |
| NCT02736552 | Compare S-1 for 6 Months to 1 Year as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer Staged II , IIIA or IIIB. | withdrawn | Phase 3 | 0 | Fudan UniversityOTHER | 1 | May 8, 2019 | clinicaltrials |
| NCT03744247 | Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC | withdrawn | Phase 3 | 0 | Sun Yat-sen UniversityOTHER | 1 | May 2, 2019 | clinicaltrials |
| NCT03791918 | Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria | withdrawn | Phase 3 | 0 | Sun Yat-sen UniversityOTHER | 1 | May 2, 2019 | clinicaltrials |
| NCT02438852 | Continuous Infusion of Ropivacaine Hydrochloride in Reducing Pain After Surgery in Patients With Bladder Cancer | withdrawn | Phase 3 | 0 | University of Southern CaliforniaOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT03717038 | Sym004 Versus TAS-102 in Patients With mCRC | withdrawn | Phase 3 | 0 | Symphogen A/SINDUSTRY | 0 | Feb 4, 2019 | clinicaltrials |
| NCT03346304 | Photodynamic Therapy for the Prevention of Lung Cancer(PEARL) | withdrawn | Phase 2 / Phase 3 | 0 | University College, LondonOTHER | 0 | Feb 1, 2019 | clinicaltrials |
| NCT03355768 | Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL | withdrawn | Phase 3 | 0 | Jennifer AmengualOTHER | 0 | Dec 19, 2018 | clinicaltrials |
| NCT03693573 | A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma | withdrawn | Phase 3 | 0 | Hoffmann-La RocheINDUSTRY | 0 | Nov 15, 2018 | clinicaltrials |
| NCT02053311 | Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents | withdrawn | Phase 3 | 0 | Swiss Cancer InstituteOTHER | 1 | Jul 30, 2018 | clinicaltrials |
| NCT00894101 | Positron Emission Tomography Imaging With [F-18] FLT Compared to [F-18] FDG in Cancer Patients for Treatment Evaluation | withdrawn | Phase 2 / Phase 3 | 0 | University of California, IrvineOTHER | 1 | Jul 20, 2018 | clinicaltrials |
| NCT02471495 | RITE-EUROPE (Radiofrequency-Induced Thermochemotherapy Effect-EUROPE) | withdrawn | Phase 3 | 0 | Medical Enterprises Europe B.V.INDUSTRY | 0 | May 7, 2018 | clinicaltrials |
| NCT02149771 | Combination Treatment for Advanced Liver Cancer | withdrawn | Phase 3 | 0 | Shanghai Zhongshan HospitalOTHER | 1 | Apr 19, 2018 | clinicaltrials |
| NCT03048136 | A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer(CheckMate 955) | withdrawn | Phase 3 | 0 | Bristol-Myers SquibbINDUSTRY | 5 | Apr 17, 2018 | clinicaltrials |
| NCT02155634 | Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma | withdrawn | Phase 3 | 0 | CelgeneINDUSTRY | 0 | Apr 10, 2018 | clinicaltrials |
| NCT01796444 | Axillary Lymph Node Dissection Versus no Dissection in Breast Cancer With Positive Sentinel Lymph Node(Z0011-China) | withdrawn | Phase 3 | 0 | Shandong Cancer Hospital and InstituteOTHER | 1 | Apr 5, 2018 | clinicaltrials |
| NCT02269696 | The Effect of Metoprolol on Anaesthesia, the Need for Analgesics, and Pain in Breast Cancer Patients | withdrawn | Phase 3 | 0 | Kuopio University HospitalOTHER | 0 | Mar 22, 2018 | clinicaltrials |
| NCT03081234 | Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer(EarLEE-2) | withdrawn | Phase 3 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Mar 15, 2018 | clinicaltrials |
| NCT01032512 | Clinical Benefits of Preoperative Nutrition Support With Enteral Immune-enhancing Formulas in Surgical Oncology | withdrawn | Phase 3 | 0 | University of ChileOTHER | 1 | Feb 19, 2018 | clinicaltrials |
| NCT03081039 | A Study of Cisplatin or Carboplatin With Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Patients With Resected or Ablation Intra-Hepatic Cholangiocarcinoma | withdrawn | Phase 3 | 0 | University of LouisvilleOTHER | 1 | Feb 19, 2018 | clinicaltrials |
| NCT02736435 | Treatment of Uterine Fibroids With Magnetic Resonance Guided High Intensity Focused Ultrasound | withdrawn | Phase 3 | 0 | Thunder Bay Regional Health Research InstituteOTHER | 1 | Feb 6, 2018 | clinicaltrials |
| NCT02784730 | Iterative PICC Placement Versus Long Term Device(PICC One Day) | withdrawn | Phase 3 | 0 | Centre Leon BerardOTHER | 1 | Feb 5, 2018 | clinicaltrials |
| NCT01762592 | REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT | withdrawn | Phase 3 | 0 | Heidelberg Pharma AGINDUSTRY | 1 | Dec 22, 2017 | clinicaltrials |
| NCT01724242 | Vaginal DHEA for Women After Breast Cancer | withdrawn | Phase 2 / Phase 3 | 0 | Hadassah Medical OrganizationOTHER | 1 | Nov 28, 2017 | clinicaltrials |
| NCT02768714 | Trial to Compare the Efficacy and Safety of Pegfilgrastim Biosimilar in Subjects With High Risk Stage Breast Cancer Receiving Chemotherapy | withdrawn | Phase 3 | 0 | Eurofarma Laboratorios S.A.INDUSTRY | 0 | Sep 15, 2017 | clinicaltrials |
| NCT01545687 | CD2 Lozenges in Preventing Acute Oral Mucositis in Patients With Head and Neck Cancer Receiving Radiotherapy and Chemotherapy | withdrawn | Phase 3 | 0 | Alliance for Clinical Trials in OncologyOTHER | 0 | Aug 8, 2017 | clinicaltrials |
| NCT01260103 | Phase 3 Study of ANP Therapy vs. TMZ for Optic Pathway Glioma | withdrawn | Phase 3 | 0 | Burzynski Research InstituteOTHER | 0 | Jul 26, 2017 | clinicaltrials |
| NCT02651610 | Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer | withdrawn | Phase 2 / Phase 3 | 0 | Peregrine PharmaceuticalsINDUSTRY | 1 | Jul 11, 2017 | clinicaltrials |
| NCT01646554 | Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases(BOS3) | withdrawn | Phase 2 / Phase 3 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | May 9, 2017 | clinicaltrials |
| NCT03070691 | Efficacy, Safety and Tolerability of Topically Applied LDE225 Cream (Hedgehog Pathway Inhibitor) in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS) | withdrawn | Phase 2 / Phase 3 | 0 | Novartis PharmaceuticalsINDUSTRY | 10 | May 5, 2017 | clinicaltrials |
| NCT00695916 | MRI in Women With Newly Diagnosed Breast Cancer Prior to Breast Conserving Surgery | withdrawn | Phase 3 | 0 | Stanford UniversityOTHER | 0 | Feb 1, 2017 | clinicaltrials |
| NCT02795884 | Adjuvant Erlotinib Intercalating Chemotherapy or Adjuvant Chemotherapy Alone in NSCLC With Common EGFR Mutation | withdrawn | Phase 3 | 0 | Yonsei UniversityOTHER | 0 | Dec 30, 2016 | clinicaltrials |
| NCT02427893 | Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma | withdrawn | Phase 3 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 15, 2016 | clinicaltrials |
| NCT01338558 | A Study of Avastin (Bevacizumab) in Combination With mFOLFOX6 in Treatment-Naïve Patients With Metastatic Colorectal Cancer With or Without K-RAS Mutations, and Comparison to Cetuximab | withdrawn | Phase 3 | 0 | Hoffmann-La RocheINDUSTRY | 0 | Nov 2, 2016 | clinicaltrials |
| NCT00061178 | Efficacy and Safety Study of rhuMAb VEGF to Treat Metastatic Renal Cell Carcinoma | withdrawn | Phase 3 | 0 | Genentech, Inc.INDUSTRY | 0 | Oct 19, 2016 | clinicaltrials |
| NCT01961934 | C11-Sodium Acetate PET/CT Imaging Evaluation in Brain Glioma, Post Therapy Necrosis and Pseudo-progression | withdrawn | Phase 2 / Phase 3 | 0 | Phoenix Molecular ImagingOTHER | 1 | Sep 28, 2016 | clinicaltrials |
| NCT00691899 | A Study to Assess the Effects of MK0822 in Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer (0822-030) | withdrawn | Phase 3 | 0 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 12, 2016 | clinicaltrials |
| NCT00692458 | A Study to Assess the Effects of MK0822 in Reducing the Risk of Bone Metastasis in Women With Breast Cancer (0822-029) | withdrawn | Phase 3 | 0 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 12, 2016 | clinicaltrials |
| NCT00041171 | Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery | withdrawn | Phase 3 | 0 | Alliance for Clinical Trials in OncologyOTHER | 0 | Jul 12, 2016 | clinicaltrials |
| NCT00053339 | Trastuzumab With or Without Tamoxifen in Treating Women With Progressive Stage IV Breast Cancer | withdrawn | Phase 3 | 0 | Alliance for Clinical Trials in OncologyOTHER | 0 | Jul 12, 2016 | clinicaltrials |
| NCT01473290 | Probiotic Therapy in Preventing Gastrointestinal Complications in Patients Undergoing Chemotherapy and Pelvic Radiation Therapy | withdrawn | Phase 3 | 0 | Alliance for Clinical Trials in OncologyOTHER | 0 | Jul 6, 2016 | clinicaltrials |
| NCT02735876 | A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma | withdrawn | Phase 3 | 0 | Acerta Pharma BVINDUSTRY | 0 | May 13, 2016 | clinicaltrials |
| NCT00531349 | Regional Anesthesia and Endometrial Cancer Recurrence(ECA/R) | withdrawn | Phase 3 | 0 | The Cleveland ClinicOTHER | 1 | May 9, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Jun 4, 2019source: clinicaltrials